Arcus Biosciences (NYSE:RCUS) Shares Gap Down – Here’s What Happened

Arcus Biosciences, Inc. (NYSE:RCUS)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $22.14, but opened at $21.26. Arcus Biosciences shares last traded at $23.9140, with a volume of 1,339,644 shares changing hands.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus reported new ARC-20 data for casdatifan in clear cell renal cell carcinoma across first-line, second-line and later-line treatment settings. The drug’s combinations showed promising response rates and progression-free survival compared with historical benchmarks, with manageable safety, supporting its potential as a broadly used kidney-cancer treatment. Arcus Presents New ARC-20 Casdatifan Data
• Positive Sentiment: Truist raised its price target to $41 and maintained a “buy” rating, while Wedbush increased its target to $49 and reiterated an “outperform” rating. The revisions reflect optimism about casdatifan’s clinical and commercial potential. Analyst Price Target Updates
• Neutral Sentiment: Analyst commentary characterized the ARC-20 results as encouraging but cautioned that pivotal trials, regulatory approval and commercial execution remain ahead. Arcus’s valuation already reflects substantial expectations, leaving the stock sensitive to clinical setbacks. Analysis of Casdatifan Data
• Neutral Sentiment: Investors are also awaiting third-quarter results, with one preview suggesting Arcus may report another loss. Earnings expectations could add volatility, although the company’s recent revenue exceeded consensus estimates. Arcus Earnings Preview
• Negative Sentiment: Arcus commenced an underwritten public offering of common stock. Because the company—not existing shareholders—is selling the shares, the financing should strengthen its cash resources but creates dilution and likely contributed to the stock’s decline. Arcus Public Offering Announcement
• Negative Sentiment: Kuehn Law said it is investigating whether Arcus officers and directors breached fiduciary duties through potential self-dealing. The announcement is only an investigation, not a finding of wrongdoing, but it adds reputational and legal uncertainty. Kuehn Law Investigation

Analysts Set New Price Targets

RCUS has been the subject of a number of research analyst reports. Morgan Stanley set a $23.00 price target on shares of Arcus Biosciences in a research note on Monday, August 10th. William Blair initiated coverage on shares of Arcus Biosciences in a report on Friday, October 16th. They issued an “outperform” rating for the company. TD Cowen started coverage on shares of Arcus Biosciences in a research note on Wednesday, September 16th. They set a “buy” rating on the stock. Wedbush boosted their target price on Arcus Biosciences from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.64.

Arcus Biosciences Price Performance

The company has a 50 day moving average of $26.53 and a two-hundred day moving average of $26.22. The firm has a market cap of $2.42 billion, a P/E ratio of -4.87 and a beta of 0.94. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. The company’s revenue for the quarter was down 74.4% on a year-over-year basis. Sell-side analysts expect that Arcus Biosciences, Inc. will post -3.55 EPS for the current year.

Insider Buying and Selling

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at approximately $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of RCUS. Integrated Wealth Concepts LLC acquired a new position in shares of Arcus Biosciences in the 2nd quarter worth $30,000. KBC Group NV acquired a new stake in shares of Arcus Biosciences during the first quarter worth $50,000. GAMMA Investing LLC raised its position in shares of Arcus Biosciences by 10.0% during the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after purchasing an additional 359 shares during the period. Nykredit A S acquired a new stake in shares of Arcus Biosciences during the second quarter worth $134,000. Finally, State of Wyoming acquired a new stake in shares of Arcus Biosciences during the second quarter worth $142,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.